Drug Profile
Zirconium-89 DFO REGN 3504
Alternative Names: 89Zr-DFO-REGN3504Latest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antibody diagnostics; Drug conjugates; Imaging agents; Immunoconjugates; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastric cancer; Liver cancer; Lung cancer; Oesophageal cancer
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Gastric-cancer(Diagnosis) in USA (IV)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Liver-cancer(Diagnosis) in USA (IV, Infusion)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Lung-cancer(Diagnosis) in USA (IV)